| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901152AAU2017901152A0 (en) | 2017-03-30 | Chimeric molecules and uses thereof | |
| PCT/AU2018/050299WO2018176103A1 (en) | 2017-03-30 | 2018-03-29 | "chimeric molecules and uses thereof" |
| Publication Number | Publication Date |
|---|---|
| SG11201908280SAtrue SG11201908280SA (en) | 2019-10-30 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908280SSG11201908280SA (en) | 2017-03-30 | 2018-03-29 | "chimeric molecules and uses thereof" |
| Country | Link |
|---|---|
| US (2) | US11254712B2 (en) |
| EP (2) | EP4512820A3 (en) |
| JP (2) | JP7291398B2 (en) |
| KR (1) | KR20190135017A (en) |
| CN (1) | CN110506060B (en) |
| AU (1) | AU2018241252B2 (en) |
| BR (1) | BR112019019813A2 (en) |
| CA (1) | CA3057171A1 (en) |
| DK (1) | DK3601367T3 (en) |
| ES (1) | ES3001108T3 (en) |
| IL (1) | IL269534B2 (en) |
| MX (1) | MX2019011599A (en) |
| PL (1) | PL3601367T3 (en) |
| SG (1) | SG11201908280SA (en) |
| WO (1) | WO2018176103A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS55162B1 (en)* | 2007-12-24 | 2017-01-31 | Id Biomedical Corp Quebec | RECOMBINANT RSV ANTIGENS |
| PL3178490T3 (en) | 2009-07-15 | 2022-08-01 | Glaxosmithkline Biologicals S.A. | Rsv f protein compositions and methods for making same |
| LT3275892T (en) | 2011-05-13 | 2020-04-10 | Glaxosmithkline Biologicals S.A. | Pre-fusion rsv f antigens |
| EP3752088B1 (en) | 2018-02-15 | 2025-03-19 | Wearne Digital Pte. Ltd. | A platform and system for use in therapeutic procedures |
| EP3875110A4 (en) | 2018-10-25 | 2022-08-03 | KM Biologics Co., Ltd. | Modified cmv gb protein and cmv vaccine including same |
| JP7454645B2 (en)* | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ, インコーポレイテッド | HIV vaccine and its production and use methods |
| US12419949B2 (en)* | 2019-07-24 | 2025-09-23 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
| JP7507244B2 (en)* | 2020-02-05 | 2024-06-27 | 山西錦波生物医薬股▲フェン▼有限公司 | Polypeptides, methods for their preparation and uses |
| EP4100420A1 (en)* | 2020-02-06 | 2022-12-14 | Boehringer Ingelheim Vetmedica GmbH | Polypeptides useful for detecting anti-rhabdovirus antibodies |
| CN112300251B (en)* | 2020-02-24 | 2022-04-05 | 成都威斯克生物医药有限公司 | Protein and vaccine for anti SARS-CoV-2 infection |
| WO2021216560A2 (en)* | 2020-04-20 | 2021-10-28 | Richard Ascione | Vaccine compositions for sars-related coronaviruses and methods of use |
| BR112022022604A2 (en)* | 2020-05-07 | 2023-03-28 | Icahn School Med Mount Sinai | RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SARS-COV-2 SPIKE PROTEIN AND ITS USES |
| JP2023528984A (en)* | 2020-06-10 | 2023-07-06 | バヴァリアン・ノルディック・アクティーゼルスカブ | Recombinant Modified Vaccinia Virus Ankara (MVA) Vaccine Against Coronavirus Disease |
| US20230256090A1 (en) | 2020-06-29 | 2023-08-17 | Glaxosmithkline Biologicals Sa | Adjuvants |
| IL300527A (en)* | 2020-08-10 | 2023-04-01 | Scripps Research Inst | Compositions and methods related to ebola virusvaccines |
| EP4204000A4 (en)* | 2020-08-26 | 2024-10-16 | The University of Queensland | MODIFIED POLYPEPTIDES WITH IMPROVED PROPERTIES |
| US11175293B1 (en) | 2021-01-04 | 2021-11-16 | University Of Utah Research Foundation | Rapid assay for detection of SARS-CoV-2 antibodies |
| PE20241071A1 (en) | 2021-01-14 | 2024-05-13 | Gilead Sciences Inc | HIV VACCINES AND METHODS OF USE |
| EP4346894A1 (en) | 2021-05-24 | 2024-04-10 | GlaxoSmithKline Biologicals S.A. | Adjuvants |
| US20240317810A1 (en)* | 2021-07-15 | 2024-09-26 | Board Of Regents, The University Of Texas System | Prefusion-stabilized chimeric hmpv-rsv f proteins |
| US20230096087A1 (en)* | 2021-09-24 | 2023-03-30 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie | Prefusion-stabilized herpesvirus glycoprotein-b |
| EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
| JP2025514622A (en)* | 2022-03-31 | 2025-05-09 | ザ ユニバーシティー オブ クイーンズランド | Improved chimeric polypeptides and uses thereof |
| WO2023196945A2 (en)* | 2022-04-08 | 2023-10-12 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof |
| AU2023339047A1 (en) | 2022-09-09 | 2025-03-20 | Repligen Corporation | Affinity agents |
| CN116789847B (en)* | 2023-01-13 | 2024-04-16 | 广州医科大学附属第一医院(广州呼吸中心) | Fusion proteins, virus-like particles and vaccines |
| WO2024186980A2 (en)* | 2023-03-08 | 2024-09-12 | Dana-Farber Cancer Institute, Inc. | Hendra virus and nipah virus surface glycoprotein peptides, conjugates, and uses thereof |
| CN119841911A (en)* | 2025-03-18 | 2025-04-18 | 北京华诺泰生物医药科技有限公司 | Human metapneumovirus F protein mutant and application thereof |
| CN120248083B (en)* | 2025-06-05 | 2025-09-30 | 腾讯科技(深圳)有限公司 | GLP-1R and GCGR double-target activating polypeptide or derivative thereof, pharmaceutically acceptable salt and application thereof |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (en) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5849572A (en) | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| ATE248924T1 (en) | 1991-05-06 | 2003-09-15 | Us Gov Health & Human Serv | CARCINOEMBRYONAL ANTIGEN-EXPRESSING RECOMBINANT VIRUSES AND METHODS OF THEIR APPLICATION |
| US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| EP1637608B1 (en) | 1993-10-25 | 2009-07-22 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| EP0783573B1 (en) | 1994-09-23 | 2005-12-21 | The University of British Columbia | Method of enhancing expression of mhc class i molecules bearing endogenous peptides |
| CA2201587C (en) | 1994-10-03 | 2002-06-25 | Jeffrey Schlom | Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
| FR2726003B1 (en) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | CULTURE MEDIUM OF AVIAN TOTIPOTENT EMBRYONIC CELLS, METHOD FOR CULTURING THESE CELLS, AND AVIAN TOTIPOTENT EMBRYONIC CELLS |
| US5801030A (en) | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| KR100643058B1 (en) | 1996-12-03 | 2006-11-13 | 아브게닉스, 인크. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| DE19650370A1 (en) | 1996-12-05 | 1998-06-10 | Basf Ag | Flame-retardant thermoplastic molding compositions based on polyarylene ethers |
| US5849561A (en) | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
| DK0985039T3 (en) | 1997-06-12 | 2008-06-09 | Novartis Int Pharm Ltd | Artificial antibody polypeptides |
| EP1002119A1 (en) | 1997-07-31 | 2000-05-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
| US6893866B1 (en) | 1997-11-28 | 2005-05-17 | The Crown In The Right Of The Queensland Department Of Health | Flavivirus expression and delivery system |
| US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| BR9912671A (en) | 1998-08-07 | 2001-05-02 | Univ Washington | Immunological antigens for herpes simplex virus and methods for their use |
| AT408615B (en) | 1998-09-15 | 2002-01-25 | Immuno Ag | NEW INFLUENCE VIRUS VACCINE COMPOSITION |
| US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| BR0013195A (en) | 1999-07-09 | 2002-07-23 | Government Of The Us Dept Of H | Production of attenuated human-bovine chimeric respiratory syncytial virus vaccines |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| ES2256265T3 (en) | 2000-06-01 | 2006-07-16 | University Of North Carolina At Chapel Hill | DUVICATED PARVOVIRUS VECTORS. |
| US7122181B2 (en) | 2000-12-19 | 2006-10-17 | Research Development Foundation | Lentiviral vector-mediated gene transfer and uses thereof |
| US7141392B2 (en)* | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| GB2372991B (en) | 2001-03-09 | 2004-11-17 | Fiocruz Fundacao Oswaldo Cruz | Flavivirus expression vector |
| JP4608210B2 (en) | 2001-05-31 | 2011-01-12 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Chimeric alphavirus replicon particles |
| AU2002322026B2 (en) | 2001-06-01 | 2008-03-13 | Acambis Inc. | Chimeric flavivirus vectors |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| WO2003012054A2 (en) | 2001-08-02 | 2003-02-13 | Institut Clayton De La Recherche | Methods and compositions relating to improved lentiviral vector production systems |
| DE60233061D1 (en) | 2001-09-06 | 2009-09-03 | Alphavax Inc | ALPHAVIRUS REPLICON VECTOR SYSTEMS |
| WO2003029412A2 (en) | 2001-10-02 | 2003-04-10 | Institut Clayton De La Recherche | Restricted expression lentivial vectors |
| FR2832423B1 (en) | 2001-11-22 | 2004-10-08 | Vivalis | EXOGENOUS PROTEIN EXPRESSION SYSTEM IN AN AVIAN SYSTEM |
| JP4364643B2 (en) | 2001-11-30 | 2009-11-18 | アメリカ合衆国 | Peptide agonists of prostate specific antigen and uses thereof |
| ES2975413T3 (en) | 2001-12-17 | 2024-07-05 | Univ Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors that contain them and their uses |
| FR2836924B1 (en) | 2002-03-08 | 2005-01-14 | Vivalis | AVIAN CELL LINES USEFUL FOR THE PRODUCTION OF INTEREST SUBSTANCES |
| US7081443B2 (en)* | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
| WO2004075861A2 (en) | 2003-02-26 | 2004-09-10 | Children's Hospital, Inc. | Recombinant adeno-associated virus production |
| US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| DK1648998T3 (en) | 2003-07-18 | 2015-01-05 | Amgen Inc | Specific binding agents for hepatocyte growth factor |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| US7550296B2 (en) | 2004-12-01 | 2009-06-23 | Bayer Schering Pharma Ag | Generation of replication competent viruses for therapeutic use |
| EP2573185A3 (en) | 2005-02-16 | 2013-06-05 | Lentigen Corporation | Lentiviral vectors and their use |
| CA2609276A1 (en) | 2005-05-23 | 2006-11-30 | De-Chu C. Tang | Rapid production of adenovirus-free recombinant adenovirus vectors |
| AR054822A1 (en) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | ADMISSION IMMUNE EMULSION |
| WO2007047706A2 (en) | 2005-10-17 | 2007-04-26 | Children's Hospital | Methods and compositions for regulating gene expression |
| BRPI0504945B8 (en) | 2005-10-31 | 2022-08-02 | Fundacao Oswaldo Cruz | METHOD FOR PRODUCTION OF RECOMBINANT FLAVIVIRUS CONTAINING NUCLEOTIDE SEQUENCES ENCODING A HETEROLOGOUS PROTEIN, DNA CONSTRUCT, FLAVIVIRUS, AND, VACCINE COMPOSITION TO IMMUNIZE AGAINST FLAVIVIRUS AND/OR OTHER PATHOGENS. |
| US20070249043A1 (en) | 2005-12-12 | 2007-10-25 | Mayall Timothy P | Adenoviral expression vectors |
| CA2659592C (en) | 2006-07-14 | 2016-10-04 | Konstantin V. Pugachev | Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins |
| EP2117588A4 (en) | 2007-02-09 | 2011-05-04 | Sanofi Pasteur Biologics Co | Viral vectors and methods of use |
| BRPI0813194B8 (en) | 2007-08-03 | 2021-05-25 | Centre Nat Rech Scient | kit, lentiviral vector particles, composition of plasmid vectors, chimeric hiv-1 derived antigen, vsv-g envelope protein, nucleic acid molecules, immunogenic composition and use of a lentiviral vector |
| WO2009114207A2 (en) | 2008-03-14 | 2009-09-17 | Sanofi Pasteur Biologics Co. | Replication-defective flavivirus vaccines and vaccine vectors |
| WO2010033722A2 (en) | 2008-09-17 | 2010-03-25 | Isogenis, Inc. | Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof |
| CA2749558C (en) | 2008-12-08 | 2019-01-15 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| HUE029037T2 (en)* | 2008-12-09 | 2017-01-30 | Novavax Inc | Modified RSV F proteins and methods of application |
| US20120128713A1 (en) | 2009-03-16 | 2012-05-24 | Sanofi Pasteur Limited | Replication-Defective Flavivirus Vaccine Vectors Against Respiratory Syncytial Virus |
| US8679837B2 (en) | 2009-04-02 | 2014-03-25 | University Of Florida Research Foundation, Inc. | Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors |
| PL3178490T3 (en) | 2009-07-15 | 2022-08-01 | Glaxosmithkline Biologicals S.A. | Rsv f protein compositions and methods for making same |
| CA2781519A1 (en)* | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| EP2486137B1 (en) | 2009-10-05 | 2018-05-30 | Ya-Fang Mei | Replication-competent ad11p based viral vectors |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US20120294889A1 (en) | 2010-11-12 | 2012-11-22 | Paxvax, Inc. | Chimeric Flavivirus Vaccines |
| ES2685611T3 (en) | 2011-02-14 | 2018-10-10 | The Children's Hospital Of Philadelphia | Enhanced VAA8 vector with increased functional activity and methods of use |
| WO2012145509A2 (en) | 2011-04-19 | 2012-10-26 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors, and viruses |
| LT3275892T (en)* | 2011-05-13 | 2020-04-10 | Glaxosmithkline Biologicals S.A. | Pre-fusion rsv f antigens |
| CA2849822C (en) | 2011-09-23 | 2021-05-11 | Gary J. Nabel, M.D. | Novel influenza hemagglutinin protein-based vaccines |
| US9506041B2 (en) | 2012-03-26 | 2016-11-29 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Delivery of packaged RNA to mammalian cells |
| ES2862912T3 (en) | 2012-04-18 | 2021-10-08 | Childrens Hospital Philadelphia | Composition and procedures for high-efficiency gene transfer using AAV capsid variants |
| US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| JP2015529466A (en) | 2012-09-14 | 2015-10-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Lentiviral vector for stem cell gene therapy of sickle cell disease |
| SG11201502221WA (en) | 2012-09-21 | 2015-05-28 | Agency Science Tech & Res | Novel attenuated dengue virus strains for vaccine application |
| KR20150085843A (en)* | 2012-11-20 | 2015-07-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Rsv f prefusion trimers |
| US9624510B2 (en) | 2013-03-01 | 2017-04-18 | The Wistar Institute | Adenoviral vectors comprising partial deletions of E3 |
| US9060975B2 (en)* | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
| US20140271708A1 (en) | 2013-03-15 | 2014-09-18 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies G |
| US20160193322A1 (en) | 2013-08-05 | 2016-07-07 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
| EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
| KR20190045213A (en)* | 2016-08-11 | 2019-05-02 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | Immune-modulating compounds |
| JP2025514622A (en) | 2022-03-31 | 2025-05-09 | ザ ユニバーシティー オブ クイーンズランド | Improved chimeric polypeptides and uses thereof |
| Publication number | Publication date |
|---|---|
| EP3601367B1 (en) | 2024-10-09 |
| EP3601367A1 (en) | 2020-02-05 |
| WO2018176103A1 (en) | 2018-10-04 |
| MX2019011599A (en) | 2019-12-19 |
| IL269534B2 (en) | 2025-01-01 |
| AU2018241252B2 (en) | 2024-09-19 |
| EP4512820A2 (en) | 2025-02-26 |
| JP7291398B2 (en) | 2023-06-15 |
| US11254712B2 (en) | 2022-02-22 |
| DK3601367T3 (en) | 2025-01-13 |
| IL269534A (en) | 2019-11-28 |
| IL269534B1 (en) | 2024-09-01 |
| US12116386B2 (en) | 2024-10-15 |
| US20200040042A1 (en) | 2020-02-06 |
| US20220127309A1 (en) | 2022-04-28 |
| CN110506060B (en) | 2024-05-07 |
| PL3601367T3 (en) | 2025-03-31 |
| EP3601367A4 (en) | 2020-09-16 |
| JP2023071901A (en) | 2023-05-23 |
| JP2020515272A (en) | 2020-05-28 |
| EP4512820A3 (en) | 2025-05-21 |
| CA3057171A1 (en) | 2018-10-04 |
| BR112019019813A2 (en) | 2020-04-22 |
| ES3001108T3 (en) | 2025-03-04 |
| AU2018241252A1 (en) | 2019-10-03 |
| KR20190135017A (en) | 2019-12-05 |
| CN110506060A (en) | 2019-11-26 |
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908280SA (en) | "chimeric molecules and uses thereof" | |
| SG11201907769XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201808783XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
| SG11201810179RA (en) | Novel crispr enzymes and systems | |
| SG11201903089RA (en) | Aav delivery of nucleobase editors | |
| SG11201803593QA (en) | Engineered nucleic-acid targeting nucleic acids | |
| SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201806398YA (en) | Optimized factor viii genes | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201907298WA (en) | Methods and compositions for gene transfer across the vasculature | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201810048VA (en) | Tri-segmented pichinde viruses as vaccine vectors | |
| SG11201901066UA (en) | Novel alkaline stable immunoglobulin-binding proteins | |
| SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
| SG11201808457PA (en) | Icos ligand variant immunomodulatory proteins and uses thereof | |
| SG11201805493YA (en) | Binding members with altered diversity scaffold domains | |
| SG11201804713VA (en) | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | |
| SG11201407866XA (en) | Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof |